Literature DB >> 21295685

The connections between neural crest development and neuroblastoma.

Manrong Jiang1, Jennifer Stanke, Jill M Lahti.   

Abstract

Neuroblastoma (NB), the most common extracranial solid tumor in childhood, is an extremely heterogeneous disease both biologically and clinically. Although significant progress has been made in identifying molecular and genetic markers for NB, this disease remains an enigmatic challenge. Since NB is thought to be an embryonal tumor that is derived from precursor cells of the peripheral (sympathetic) nervous system, understanding the development of normal sympathetic nervous system may highlight abnormal events that contribute to NB initiation. Therefore, this review focuses on the development of the peripheral trunk neural crest, the current understanding of how developmental factors may contribute to NB and on recent advances in the identification of important genetic lesions and signaling pathways involved in NB tumorigenesis and metastasis. Finally, we discuss how future advances in identification of molecular alterations in NB may lead to more effective, less toxic therapies, and improve the prognosis for NB patients.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21295685      PMCID: PMC3633592          DOI: 10.1016/B978-0-12-380916-2.00004-8

Source DB:  PubMed          Journal:  Curr Top Dev Biol        ISSN: 0070-2153            Impact factor:   4.897


  279 in total

1.  Marked and independent prognostic significance of the CpG island methylator phenotype in neuroblastomas.

Authors:  Masanobu Abe; Frank Westermann; Akira Nakagawara; Tsuyoshi Takato; Manfred Schwab; Toshikazu Ushijima
Journal:  Cancer Lett       Date:  2006-06-06       Impact factor: 8.679

2.  Potentiation of neuroblastoma metastasis by loss of caspase-8.

Authors:  Dwayne G Stupack; Tal Teitz; Matthew D Potter; David Mikolon; Peter J Houghton; Vincent J Kidd; Jill M Lahti; David A Cheresh
Journal:  Nature       Date:  2006-01-05       Impact factor: 49.962

3.  Programmed cell death is a universal feature of embryonic and postnatal neuroproliferative regions throughout the central nervous system.

Authors:  A J Blaschke; J A Weiner; J Chun
Journal:  J Comp Neurol       Date:  1998-06-22       Impact factor: 3.215

4.  Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children's Cancer Group study.

Authors:  K K Matthay; C Perez; R C Seeger; G M Brodeur; H Shimada; J B Atkinson; C T Black; R Gerbing; G M Haase; D O Stram; P Swift; J N Lukens
Journal:  J Clin Oncol       Date:  1998-04       Impact factor: 44.544

5.  Cytogenetic evolution of MYCN and MDM2 amplification in the neuroblastoma LS tumour and its cell line.

Authors:  R Corvi; L Savelyeva; L Amler; R Handgretinger; M Schwab
Journal:  Eur J Cancer       Date:  1995       Impact factor: 9.162

6.  Imbalance of the mitochondrial pro- and anti-apoptotic mediators in neuroblastoma tumours with unfavourable biology.

Authors:  Frida Abel; Rose-Marie Sjöberg; Staffan Nilsson; Per Kogner; Tommy Martinsson
Journal:  Eur J Cancer       Date:  2005-03       Impact factor: 9.162

7.  PPM1D is a potential target for 17q gain in neuroblastoma.

Authors:  Fumiko Saito-Ohara; Issei Imoto; Jun Inoue; Hajime Hosoi; Akira Nakagawara; Tohru Sugimoto; Johji Inazawa
Journal:  Cancer Res       Date:  2003-04-15       Impact factor: 12.701

Review 8.  Current aspects of biology, risk assessment, and treatment of neuroblastoma.

Authors:  G M Haase; C Perez; J B Atkinson
Journal:  Semin Surg Oncol       Date:  1999-03

Review 9.  Caspase activation - stepping on the gas or releasing the brakes? Lessons from humans and flies.

Authors:  Guy S Salvesen; John M Abrams
Journal:  Oncogene       Date:  2004-04-12       Impact factor: 9.867

Review 10.  Comprehensive genomics linking between neural development and cancer: neuroblastoma as a model.

Authors:  Akira Nakagawara; Miki Ohira
Journal:  Cancer Lett       Date:  2004-02-20       Impact factor: 8.679

View more
  56 in total

1.  Multiscale mechanisms of cell migration during development: theory and experiment.

Authors:  Rebecca McLennan; Louise Dyson; Katherine W Prather; Jason A Morrison; Ruth E Baker; Philip K Maini; Paul M Kulesa
Journal:  Development       Date:  2012-07-04       Impact factor: 6.868

Review 2.  Genetically engineered murine models--contribution to our understanding of the genetics, molecular pathology and therapeutic targeting of neuroblastoma.

Authors:  Louis Chesler; William A Weiss
Journal:  Semin Cancer Biol       Date:  2011-09-21       Impact factor: 15.707

3.  Functional Enhancers Shape Extrachromosomal Oncogene Amplifications.

Authors:  Andrew R Morton; Nergiz Dogan-Artun; Zachary J Faber; Graham MacLeod; Cynthia F Bartels; Megan S Piazza; Kevin C Allan; Stephen C Mack; Xiuxing Wang; Ryan C Gimple; Qiulian Wu; Brian P Rubin; Shashirekha Shetty; Stephane Angers; Peter B Dirks; Richard C Sallari; Mathieu Lupien; Jeremy N Rich; Peter C Scacheri
Journal:  Cell       Date:  2019-11-21       Impact factor: 41.582

4.  Temozolomide may induce cell cycle arrest by interacting with URG4/URGCP in SH-SY5Y neuroblastoma cells.

Authors:  Veli Çıtışlı; Yavuz Dodurga; Canan Eroğlu; Mücahit Seçme; Çığır Biray Avcı; N Lale Şatıroğlu-Tufan
Journal:  Tumour Biol       Date:  2015-04-03

5.  Sub-micromolar concentrations of retinoic acid induce morphological and functional neuronal phenotypes in SK-N-SH neuroblastoma cells.

Authors:  Emily Harasym; Nicole McAndrew; George Gomez
Journal:  In Vitro Cell Dev Biol Anim       Date:  2017-08-24       Impact factor: 2.416

6.  Combined epigenetic and differentiation-based treatment inhibits neuroblastoma tumor growth and links HIF2α to tumor suppression.

Authors:  Isabelle Westerlund; Yao Shi; Konstantinos Toskas; Stuart M Fell; Shuijie Li; Olga Surova; Erik Södersten; Per Kogner; Ulrika Nyman; Susanne Schlisio; Johan Holmberg
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-10       Impact factor: 11.205

Review 7.  Cancer Stem Cells and Neuroblastoma: Characteristics and Therapeutic Targeting Options.

Authors:  Veronica Veschi; Francesco Verona; Carol J Thiele
Journal:  Front Endocrinol (Lausanne)       Date:  2019-11-19       Impact factor: 5.555

8.  Tideglusib attenuates growth of neuroblastoma cancer stem/progenitor cells in vitro and in vivo by specifically targeting GSK-3β.

Authors:  Hisham F Bahmad; Reda M Chalhoub; Hayat Harati; Georges Daoud; Youssef Fares; Wassim Abou-Kheir; Jolie Bou-Gharios; Sahar Assi; Farah Ballout; Alissar Monzer; Hiba Msheik; Tarek Araji; Mohamad K Elajami; Paola Ghanem; Farah Chamaa; Humam Kadara; Tamara Abou-Antoun
Journal:  Pharmacol Rep       Date:  2020-10-08       Impact factor: 3.024

Review 9.  Organelle asymmetry for proper fitness, function, and fate.

Authors:  Dorothy A Lerit; Jeremy T Smyth; Nasser M Rusan
Journal:  Chromosome Res       Date:  2013-05       Impact factor: 5.239

10.  G-CSF receptor positive neuroblastoma subpopulations are enriched in chemotherapy-resistant or relapsed tumors and are highly tumorigenic.

Authors:  Danielle M Hsu; Saurabh Agarwal; Ashley Benham; Cristian Coarfa; Denae N Trahan; Zaowen Chen; Paris N Stowers; Amy N Courtney; Anna Lakoma; Eveline Barbieri; Leonid S Metelitsa; Preethi Gunaratne; Eugene S Kim; Jason M Shohet
Journal:  Cancer Res       Date:  2013-05-16       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.